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Abstract: Many cross-sectional studies show an inverse association between dietary 
magnesium and insulin resistance, but few longitudinal studies examine the ability to meet 
the Recommended Dietary Allowance (RDA) for magnesium intake through food and its 
effect on insulin resistance among participants with metabolic syndrome (MetS). The dietary 
intervention study examined this question in 234 individuals with MetS. Magnesium intake 
was assessed using 24-h dietary recalls at baseline, 6, and 12 months. Fasting glucose and 
insulin levels were collected at each time point; and insulin resistance was estimated by the 
homeostasis model assessment (HOMA-IR). The relation between magnesium intake and 
HOMA-IR was assessed using linear mixed models adjusted for covariates. Baseline 
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magnesium intake was 287 ± 93 mg/day (mean ± standard deviation), and HOMA-IR, 
fasting glucose and fasting insulin were 3.7 ± 3.5, 99 ± 13 mg/dL, and 15 ± 13 μU/mL, 
respectively. At baseline, 6-, and 12-months, 23.5%, 30.4%, and 27.7% met the RDA for 
magnesium. After multivariate adjustment, magnesium intake was inversely associated 
with metabolic biomarkers of insulin resistance (P < 0.01). Further, the likelihood of 
elevated HOMA-IR (>3.6) over time was 71% lower [odds ratio (OR): 0.29; 95% 
confidence interval (CI): 0.12, 0.72] in participants in the highest quartile of magnesium 
intake than those in the lowest quartile. For individuals meeting the RDA for magnesium, 
the multivariate-adjusted OR for high HOMA-IR over time was 0.37 (95% CI: 0.18, 0.77). 
These findings indicate that dietary magnesium intake is inadequate among non-diabetic 
individuals with MetS and suggest that increasing dietary magnesium to meet the RDA has 
a protective effect on insulin resistance. 
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1. Introduction 
Magnesium is a vital nutrient responsible for over 300 biochemical reactions in the body including 
regulation of blood sugar levels, blood pressure, and bone health [1]. Foods rich in magnesium are also 
typically high in dietary fiber such as dark green vegetables, legumes, nuts, and whole grains. A 
necessary cofactor in glucose metabolism, magnesium has been implicated in a number of health 
conditions, including metabolic syndrome [2]. In an updated meta-analysis of 13 prospective cohort 
studies involving 536,318 participants and 24,516 cases, an inverse association was significant 
between magnesium intake and risk of type 2 diabetes [pooled relative risk and 95% confidence interval 
(CI) = 0.78 (0.73–0.84)] [3]. Another meta-analysis of nine randomized double-blind controlled trials 
with a total of 370 patients with type 2 diabetes, who were given oral magnesium supplementation for  
4–16 weeks, found that it may reduce plasma fasting glucose levels in the treatment groups compared 
with placebo [−0.56 mmol/L (95% CI, −1.10 to −0.01)] but had no effect on hemoglobin A1c between 
both groups [−0.31% (95% CI, −0.81 to 0.19)] [4]. Some cross-sectional studies and one longitudinal 
study showed an inverse correlation between magnesium intake and insulin resistance in diabetic patients 
and normal individuals [5–9]. Two clinical trials indicated that oral magnesium supplementation could 
improve insulin sensitivity or insulin resistance in non-diabetic subjects [10,11]. However, the majority 
of studies examined participants with diabetes, with few longitudinal studies exploring this relationship 
among non-diabetic individuals with metabolic syndrome (MetS). 
A national study revealed that most U.S. adults failed to consume adequate intakes of magnesium in 
their diet [12]. Previous studies have yet to evaluate if insulin resistance is related to this failure in 
meeting the Recommended Dietary Allowances (RDA) for magnesium. The present study examined 
the longitudinal association of magnesium intake (from food) and insulin resistance in non-diabetic 
participants with MetS, while also exploring insulin resistance as it relates to the RDA guidelines for 
magnesium intake. Nutrients 2013, 5  3912 
 
2. Methods 
2.1. Study Sample 
Details of the “Can Do” study methodology have been described elsewhere [13]. Briefly, 
participant recruitment commenced at the University of Massachusetts Medical School (UMMS), 
Worcester, Massachusetts, USA, in May 2009 and was completed in February 2013. The study 
protocol was approved by the UMMS Institutional Review Board for use of human subjects in medical 
research and all participants gave informed consent. A total of 234 non-diabetic men and women who 
had a BMI ≥30 and ≤40 kg/m
2 and met three or more components of MetS [14], and did not have a 
fasting blood sugar >126 mg/dL, were enrolled and randomized into one of the two dietary 
interventions: a high fiber diet or the American Heart Association (AHA) diet. In the high fiber diet 
condition, participants received instruction to achieve a daily dietary fiber intake goal of 30 g or more 
from a variety of food sources. Patients in AHA diet group were instructed to make dietary changes 
addressing both macro- and micronutrients as recommended by the AHA 2006 dietary guidelines [15]. 
2.2. Participant Characteristics 
Demographics including age, race/ethnicity, education, marital status, household income, and 
employment status were collected at baseline. Weight, height, waist circumference, blood pressure, 
high-density lipoprotein cholesterol, triglycerides, fasting plasma insulin and glucose, and physical 
activity were measured at baseline, 6-month, and 12-month visits. Body Mass Index (BMI) was 
calculated for each time point [BMI = weight (kg)/(height(m))
2] and was categorized as mild [class I, 
BMI 30 to 34.99] or moderate (class II, BMI 35 to 40) obesity. Serum was collected after a 12-h fast 
between the hours of 7:00 am and 10:00 am and stored at −80 °C. To measure insulin, IMMUNLITE 
2000 insulin was used, it is a solid-phase, enzyme-labeled chemiluminescent immunometric assay. The 
SYNCHRON LX System was used to measure glucose, it determines GLUCm concentration by an 
oxygen rate method employing a Beckman Coulter oxygen electrode. Insulin resistance, assessed by 
the homeostasis model assessment (HOMA-IR), was calculated as follows: HOMA-IR = fasting 
plasma insulin (μU/mL) × fasting plasma glucose (mg/dL)/405 [16]. A cutoff of HOMA-IR >3.6 was 
considered to be insulin resistant [17]. 
2.3. Dietary Assessment 
Food intake was assessed at baseline, 6-, and 12-month visits by trained registered dietitians via 
three 24-h dietary recalls using the Nutritional Data System for Research (NDS-R) software [18], 
which is developed and annually updated by the Nutrition Coordinating Center, University of 
Minnesota, Minneapolis, MN. The 24-h dietary recalls were randomly collected on two weekdays and 
one weekend day by study dietitians within a three-week window at baseline, 6-, and 12-month visits. 
All participants received a food portion visual booklet prior to receiving the assessment calls to 
facilitate portion size estimation. The nutrient data collected from 24-h dietary recalls were analyzed. Nutrients 2013, 5  3913 
 
2.4. Statistical Analysis 
Since there were no statistically significant differences between the AHA and High Fiber diet group 
for magnesium intake, we pooled data from both groups to increase statistical power for this secondary 
analysis. Natural logarithm transformation of HOMA-IR, fasting plasma glucose, and fasting plasma 
insulin were used since distributions were right-skewed. The outcome variable HOMA-IR was 
analyzed as both a continuous and a dichotomous variable. 
Magnesium intake was included as both a continuous and two types of categorical variables 
(quartiles or met recommendation). Cut-points for meeting the RDA for magnesium were determined 
according to the Institute of Medicine of the National Academy of Sciences recommendation for 
adults: 19–30 years, 400 mg/day (men) and 310 mg/day (women); 31 years and older, 420 mg/day (men) 
and 320 mg/day (women). This analysis focused on the RDA, not to be confused with the Estimated 
Average Requirements (EAR), which is actually lower than the RDA. EAR for magnesium for men, 
ages 19–30, is 330 mg/day and over 31 years and older is 350 mg/day; while for women, ages 19–30, 
it is 255 mg/day and for 31 and over it is 265 mg/day [19]. 
Dietary calcium, potassium, sodium, zinc, total calories, total fiber, and ratio of calcium-to-magnesium 
were considered in bivariate analyses to assess potential confounding. Gender, race/ethnicity, high 
triglycerides, BMI, and intervention group were considered as covariates due to their potential 
associations with insulin resistance. 
For the continuous metabolic biomarker variables, we used two linear mixed models with random 
intercepts. In Model 1, we examined the association between dietary magnesium and HOMA-IR and 
intervention conditions over the 12-month study period; and in Model 2, we examined the association 
between dietary magnesium and metabolic biomarkers  adjusting for important covariates over the 
study period. 
To evaluate the association between magnesium and insulin resistance defined as HOMA-IR more 
than 3.6, generalized linear mixed models (GLIMMIX) were used to compute the odds ratios (ORs) 
and 95% CIs. All analyses were performed using SAS version 9.2 software [20]. 
3. Results 
At baseline, 6, and 12 months, the dietary magnesium intake was 287 ± 93 mg/day, 307 ± 103 mg/day, 
and 295 ± 107 mg/day, (P = 0.016) and 23.5%, 30.4%, and 27.7% of subjects met the RDA of dietary 
magnesium intake (χ
2 = 2.601, P = 0.272) (data not shown). Of the subjects, 75% were women and 
86% were White. The mean waist circumference, systolic blood pressure, high-density lipoprotein 
cholesterol (HDL-C), and triglycerides were all higher than the diagnostic standard of MetS, while the 
mean for diastolic blood pressure and fasting plasma glucose was lower than the diagnostic standards 
of MetS. Characteristics of subjects at baseline by quartiles of magnesium intake are presented in 
Table 1. In the highest quartile, there were fewer females, more White individuals and higher total 
energy and fiber. Nutrients 2013, 5  3914 
 
Table 1. Baseline characteristics according to total magnesium intake quartiles among   
non-diabetic individuals with metabolic syndrome (n = 234). 
Characteristics 
Dietary Magnesium (mg/day) 
P Value 
1 Q1  
(Lowest Quartile, 
Median = 206.5)
Q2  
(Median = 258.3)
Q3  
(Median = 322.5)
Q4  
(Highest Quartile, 
Median = 385.2) 
N  59 58  58 59   
Continuous variable 
2         
Age (year)  52 ± 11  52 ± 11  52 ± 9  53 ± 10  0.906 
Waist circumference (cm)  102 ± 8  101 ± 9  102 ± 9  103 ± 9  0.628 
Systolic blood pressure (mmHg)  135 ± 9  138 ± 8  134 ± 12  137 ± 9  0.255 
Diastolic blood pressure (mmHg)  80 ± 10  81 ± 9  79 ± 8  81 ± 7  0.724 
HDL-C (mg/dL) 
3  48 ± 10  47 ± 9  48 ± 11  48 ± 11  0.787 
Triglycerides (mg/dL)
 3  124 ± 62  154 ± 62  168 ± 99  157 ± 72  0.004 
Fasting plasma glucose (mg/dL)
 3  100 ± 15  100 ± 12  96 ± 12  100 ± 11  0.347 
Fasting plasma insulin (μU/mL)
 3  17 ± 12  13 ± 12  16 ± 16  12 ± 9  0.068 
HOMA insulin resistance 
3  4.2 ± 3.4  3.4 ± 3.7  3.9 ± 4.1  3.0 ± 2.5  0.107 
Total fiber intake (mg/day)  13 ± 6  16 ± 3  21 ± 4  26 ± 6  <0.001
Total energy (kcal/day)  1392 ± 405  1691 ± 393  1974 ± 453  2452 ± 732  <0.001
Physical activity (MET: h/day)  27 ± 3  28 ± 4  28 ± 4  29 ± 5  0.117 
Categorical variable [n (%)]         
Female  51 (86%)  40 (69%)  44 (76%)  35 (59%)  0.009 
White  44 (75%)  54 (93%)  53(91%)  57 (97%)  <0.001
Married  35 (59%)  47 (81%)  36 (62%)  38 (64%)  0.057 
Education          
High school or less  10 (17%)  6 (10%)  9 (15%)  7 (12%)  0.709 
Bachelor’s degree or less  36 (61%)  36 (62%)  38 (66%)  32 (56%)   
Graduate/professional  13 (22%)  16 (28%)  11 (19%)  18 (32%)   
Household income         
$0–$30,000  8 (14%)  3 (5%)  8 (14%)  5 (8%)  0.431 
$30,000–$50,000  8 (14%)  13 (22%)  9 (16%)  11 (19%)   
$50,000–$75,000  13 (22%)  7 (12%)  9 (16%)  9 (16%)   
More than $75,000  13 (22%)  25 (43%)  20 (34%)  20 (34%)   
Unclear  17 (29%)  10 (17%)  12 (21%)  14 (24%)   
Employed full-time or part-time  18 (31%)  11 (19%)  12 (21%)  9 (16%)  0.243 
BMI (30–34.9 kg/m
2)  21 (36%)  33 (57%)  32 (55%)  27 (46%)  0.046 
HDL-C: High-density lipoprotein cholesterol; HOMA: Homeostasis model of assessment; BMI: Body mass index;   
1 P values are for any difference across the quintiles of magnesium intake using ANOVA, or χ
2 test as appropriate;  
2 All continuous variables values are mean ± standard deviation; 
3 P values based on log-transformed outcomes. Values 
presented in rows have been transformed back to original units. 
Table 2 presents the regression coefficients (β) of dietary magnesium intake and metabolic 
biomarkers of insulin resistance using a linear mixed model. Time-point and group were analyzed in 
Model 1; Model 2 included additional adjustment for gender, race/ethnicity, triglycerides, and BMI 
category. For both Model 1 and Model 2 significant inverse associations were observed between 
metabolic biomarkers of insulin resistance and magnesium intake. High BMI and female participants 
showed significant positive association with metabolic biomarkers and high insulin resistance status in Nutrients 2013, 5  3915 
 
linear mixed models. As total calories, total fiber, sodium, potassium, calcium, zinc, and ratio of 
calcium-to-magnesium could be potential confounders, we also evaluated their relationship with 
metabolic biomarkers using the same statistical models (data not shown). The only significant 
relationship with metabolic biomarkers was magnesium intake. 
Table 2. Regression coefficients (β) of magnesium intake and metabolic biomarkers of 
insulin resistance according to a linear mixed model among non-diabetic individuals with 
metabolic syndrome (n = 234) 
1. 
Dietary factors 
Model 1 
2 Model  2 
3 
β 95%  CI  P  β 95%  CI  P 
Ln insulin  −0.00073 −0.00133, −0.00013 0.016 −0.00095  −0.00155, −0.00035 0.002 
Ln glucose  −0.00009 −0.00019, −0.00001 0.048 −0.00015  −0.00024, −0.00005 0.002 
Ln HOMA-IR  −0.00082 −0.00145, −0.00019 0.011 −0.00110  −0.00173, −0.00046 <0.001 
CI: confidence intervals; HOMA-IR: Homeostasis model of assessment-Insulin resistance; Ln: natural logarithm;   
1 Estimated by PROC MIXED in SAS; 
2 Adjusted for group and time-point; 
3 Adjusted for gender, race/ethnicity, BMI 
category, triglycerides, group, and time-point. 
Total energy and total dietary fiber were highly correlated with magnesium intake (r = 0.62 and  
r = 0.78, respectively; both P values < 0.001). We analyzed Model 2 with additional adjustment for 
calories and fiber and results were slightly attenuated toward the null, however significant associations 
for magnesium remained (data not shown). 
To examine the magnesium dose-response, and if the RDA for intake was met, we examined 
quartiles of magnesium intake with the outcome of HOMA-IR >3.6 (Table 3). Magnesium intake 
category variables were assessed over three time-points using linear mixed models. After adjustment 
for covariates, the likelihood of elevated HOMA-IR (>3.6) over time was 71% lower (OR: 0.29;   
95% CI: 0.12, 0.72) in participants in the highest quartile of dietary magnesium intake than those in the 
lowest quartile at baseline. The multivariate-adjusted OR of high HOMA-IR over time for those that 
did not meet the magnesium RDA was 0.37 (95% CI: 0.18, 0.77). Evaluation of the association 
between HOMA-IR over time by magnesium intake at baseline, indicated similar odds ratios   
[(0.19, 95% CI: 0.06, 0.59) and (0.33, 95% CI: 0.13, 0.85), respectively] (data not shown in Table 3). 
Table 3. Odds ratios (OR) and 95% conference intervals (CIs) of elevated HOMA-IR 
(>3.6) over three time-points from a linear mixed model among non-diabetic individuals 
with metabolic syndrome (n = 234) 
1. 
Dietary magnesium  
intake (mg/day) 
Unadjusted Adjusted 
2 
OR  95% CI  OR  95% CI 
Quartile 1 (Median = 206.5) 1.00  Referent  1.00  Referent 
Quartile 2 (Median = 258.3)  0.51  0.23, 1.11  0.49  0.22, 1.08 
Quartile 3 (Median = 322.5)  0.82  0.36, 1.87  0.79  0.35, 1.79 
Quartile 4 (Median = 385.2)  0.40  0.16, 0.98  0.29  0.12, 0.72 
Not met RDA  1.00  Referent  1.00  Referent 
Met RDA  0.42  0.20, 0.88  0.37  0.18, 0.77 
OR: odds ratio; CI: confidence intervals; HOMA-IR: Homeostasis model of assessment-Insulin resistance; RDA: 
recommended Daily Allowance; 
1 Estimated by PROC GLIMMIX in SAS; 
2 Adjusted for gender, marital status, 
race/ethnicity, BMI category, triglycerides, group, and time-point. Nutrients 2013, 5  3916 
 
4. Discussion 
In this study, we found an inverse association between magnesium intake and insulin, glucose, and 
HOMA-IR, and that a higher level of magnesium intake from foods was protective against insulin 
resistance in non-diabetic participants with MetS. Magnesium is required for glucose utilization and 
insulin signaling. Lower intake of foods rich in magnesium may lead to metabolic alterations in 
cellular magnesium and may affect the development of insulin resistance by altering the glucose entry 
into the cell [5,21]. Some dietary factors may confound the relationship between magnesium intake 
and insulin resistance, as magnesium occurs in foods that also contain other food components, such as 
phytonutrients, fiber, and other minerals. However, in our study, metabolic biomarkers of insulin 
resistance were tested for associations with these potential confounders using the same model with 
magnesium intake, and were found to be non-significant, suggesting that dietary magnesium may 
improve insulin resistance independently. Our findings are consistent with results from previous 
studies that cite the role of magnesium as a crucial component in improving insulin resistance [22,23] 
Prior studies examining magnesium and insulin resistance confirm our findings, though more data is 
needed to continue further study for patients with metabolic syndrome. Although our study examined 
RDA, according to a publication by Hunt and Johnson, most Americans do not meet the EAR for 
magnesium, and since data on EAR is derived from a small amount of studies, they suggest that a 
reduction in the magnesium requirement for healthy men and women is warranted [24]. If the 
standards are further reduced in the future, it would be interesting to examine the impact these 
recommendations might have in a population with metabolic syndrome as our study found only a small 
percentage of participants who were able to meet the magnesium RDA. Indeed, further inquiry into the 
appropriate threshold of magnesium intake is needed to address population health in the United States. 
Our study has several limitations. Our intervention focused only on food derived items and not on 
supplements, but would make for an interesting topic of further study as Fulgoni et al. noted that there 
is “very limited information on usual micronutrient intakes from dietary supplements in the United 
States population (with the exception of folate)” [25].  The possibility of confounding from 
supplements or unknown factors cannot be ruled out, though the potential misclassification will result 
in attenuation of inverse association. In addition this study measured magnesium intake using three  
24-h dietary recalls, which have the potential to be subject to reporting bias, as study participants with 
MetS have been shown to systematically underreport their food intake [26]. Despite these potential 
drawbacks, 24-h dietary recalls are currently considered the “gold standard” of dietary research for 
micronutrients [27]. 
This investigation also has several strengths, including its longitudinal study design using   
non-diabetic participants with MetS. The majority of previous findings are cross-sectional studies 
using normal populations or those with diabetes. Although previous studies have evaluated the 
protective effect of magnesium, satisfying the RDA is a simple message that can have important 
clinical meaning. Our findings offer a unique contribution that meeting the RDA for magnesium may 
demonstrate a protective effect on insulin resistance. Nutrients 2013, 5  3917 
 
5. Conclusions 
This study observed a low percentage of participants who actually met the magnesium RDA, 
suggesting that increasing dietary magnesium to meet the RDA is associated with improving insulin 
resistance among non-diabetic  individuals with MetS. Since this population has a higher risk of 
cardiovascular disease and type 2 diabetes, dietary behaviors that have the ability to impact insulin 
resistance can have far-reaching clinical implications. The results of this study merit further 
investigation into the understudied role of adequate magnesium intake and its role in improving insulin 
resistance in this population. 
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